The raw data underlying the process of BMQ validation are available in Mendeley Data repository (<http://dx.doi.org/10.17632/rvxcb9p2md.1>).

Introduction {#sec006}
============

The effectiveness of drug therapy is not only a function of the pharmacological properties of the drug and the physiology of the patient, but also adherence to a drug regimen \[[@pone.0230131.ref001]\]. It is estimated that almost a half of chronically-ill patients do not follow the prescribed dosing regimen \[[@pone.0230131.ref002]--[@pone.0230131.ref004]\], making non-adherence one of the most important factors contributing to treatment failure \[[@pone.0230131.ref005]--[@pone.0230131.ref008]\], and many other unfavorable social and economic effects \[[@pone.0230131.ref002], [@pone.0230131.ref009]\]. Understanding and overcoming patient non-adherence is considered a major goal in healthcare \[[@pone.0230131.ref008]\] and the subject of improving adherence has attracted much attention \[[@pone.0230131.ref010]\].

There are many factors shaping adherence to a treatment protocol. One is based on the beliefs of the patients about their medications \[[@pone.0230131.ref010]--[@pone.0230131.ref012]\]. Many studies have found a negative perception of medications on the part of the patient to be a barrier to adherence \[[@pone.0230131.ref011]\]. For example, Horne and Weinman \[[@pone.0230131.ref013]\] report that having fewer concerns about taking prescribed medications and stronger perceptions of their necessity are positively associated with the self-reported medication adherence in groups of chronically-ill patients. These results were confirmed by a meta-analysis of data from more than 25,000 patients \[[@pone.0230131.ref014]\] and the use of a more objective measure of medication adherence calculated by pharmacy dispensing records \[[@pone.0230131.ref015]\]. Also, studies based on qualitative methods have confirmed the importance of patient concerns about medications as a key barrier to adherence \[[@pone.0230131.ref016]--[@pone.0230131.ref017]\]. Moreover, acknowledging patient concerns about medications and positive reinforcement of the need for medication have the potential to improve adherence and quality of life among patients \[[@pone.0230131.ref018]\].

The conceptualization and operationalization of patient beliefs about medications is challenging. However, a measure intended to assess the cognitive representation of medication, namely the Beliefs about Medicines Questionnaire (BMQ), was developed by Horne et al. \[[@pone.0230131.ref019]\]. The measure is well theoretically and scientifically grounded, supported by multiple qualitative and quantitative studies. It is intended to self-assess commonly-held beliefs about medicines, being adequate for patients suffering from a range of chronic illnesses. The questionnaire is an 18-item measure requiring assessment of each item in a 5-point Likert scale ([Fig 1](#pone.0230131.g001){ref-type="fig"}). The BMQ has become the leading tool for measuring beliefs about medicines. The paper reporting the development of the questionnaire has already been cited 1,779 times (according to *Google Scholar*--February 13, 2020) and the questionnaire was adapted to multiple languages \[[@pone.0230131.ref020]\]. The BMQ has already been used in Poland, however, the process of its adaptation to and validation in Polish language has not been reported \[[@pone.0230131.ref021]\], and no official version of the questionnaire exists. Indeed, it is of ultimate importance to ensure the validity of the used measures in order to confirm integrity of any reported research outcomes \[[@pone.0230131.ref022]\].

![Composition of the Beliefs about Medicines Questionnaire.\
More recent versions have added an item to the *Specific-Concerns* subscale and a 4-item *Benefit* subscale of the BMQ-General creating a total of 23-item questionnaire; however, no full validation of such tool has been performed \[[@pone.0230131.ref023]\].](pone.0230131.g001){#pone.0230131.g001}

Therefore, the aim of this study was to adapt the original BMQ tool to the Polish language (BMQ-PL) and to validate it.

Materials and methods {#sec007}
=====================

The adaptation of the BMQ to Polish was guided by Tsang et al. \[[@pone.0230131.ref024]\].

Ethical considerations {#sec008}
----------------------

The study was carried out in agreement with the latest version of the Declaration of Helsinki. It was approved by the Bioethics Committee of the Medical University of Lodz (number RNN/319/17/KE received on October 17, 2017). All the questionnaires were gathered from May 2018 to March 2019. In all cases, written or electronic informed consent to participate was given by the respondent.

Questionnaire forward translation {#sec009}
---------------------------------

Permission to translate and validate the BMQ was obtained from prof. Robert Horne, the leading developer of the original English version of the questionnaire \[[@pone.0230131.ref019]\]. The original BMQ was independently translated to Polish by 2 native speakers of Polish who are proficient in English: a medical doctor and a pharmacist, both with academic and clinical experience. To support accuracy and unambiguity of the final translated version, several fully validated different language versions of the BMQ were used for reference during the translation process, particularly the French \[[@pone.0230131.ref025]\] and Scandinavian \[[@pone.0230131.ref026]\].

Review of the translated version {#sec010}
--------------------------------

A panel of Polish native experts was formed to discuss the forward translations of the BMQ. The panel included 2 BMQ translators (see above) and, additionally, a psychologist, an academic English language teacher and a medical student. The panel thoroughly considered and discussed the semantics of the introduction to the questionnaire, each of the 18 statements, and rating scale labels. Afterwards, a single translated version was chosen. This version was reviewed by a specialist in Polish linguistics and further modified according to her suggestions.

Six people were then interviewed. All were non-medically educated, elderly general or cardiovascular patients with no apparent cognitive impairment; 4 women and 2 men took part, mean age 67.5 ± 11.9 years; their level of education ranged from primary to higher. The interview was performed in a semi-structured way according to general guidelines \[[@pone.0230131.ref027]\] and a protocol for questionnaire pretesting \[[@pone.0230131.ref028]\]. The aim of the interview was to assess the degree of understanding of the introduction, each of the 18 statements, and the rating scale labels of the translated questionnaire. The feedback received was used to construct the final Polish version of the Beliefs about Medicines Questionnaire (BMQ-PL, © prof. Robert Horne) and to complement further quantitative analysis. Written informed consent was received from all participants before taking part.

Questionnaire back-translation {#sec011}
------------------------------

A British native speaker who is a professional English language editor at the Medical University of Lodz, who lives in Poland and speaks Polish well, was asked to do a back-translation of the BMQ-PL (Polish to English). The translator did not participate in the expert panel and was blinded to the content of the original BMQ. After completing the back-translation, the translator was shown the original BMQ and was asked to compare it with a back-translated version of BMQ-PL in order to report the potential discrepancies of the meaning.

Understanding of the BMQ-PL {#sec012}
---------------------------

The BMQ-PL was administered in electronic form (Google Forms, Google, Mountain View, CA, USA) to a group of 14 people (8 non-medically educated general patients and 6 medical students: 6 were women, mean age 38.6 ± 19.0 years), who were asked in a structured way how much each statement in the questionnaire is understandable (unambiguous and raising no doubts) and readable (easy and enjoyable to read). A 5-point Likert scale with anchors of "not at all" (1) to "very much" (5) was used to gather the responses. The respondents were also asked to provide their own understanding of each statement in the questionnaire. Informed consent was received in electronic form from all participants.

Readability of the BMQ-PL {#sec013}
-------------------------

To further assess the readability of the BMQ-PL, the introduction to the questionnaire together with all the statements were subjected to analysis using *Jasnopis* (<https://jasnopis.pl/>): a tool to assess the difficulty of a Polish language text on a 7 degree scale \[[@pone.0230131.ref029]\].

Further validation of the questionnaire {#sec014}
---------------------------------------

Further analyses were performed to validate the BMQ-PL questionnaire: to assess and compare the data-to-model fit among Polish cardiovascular patients and medical students and to define the internal consistency of the BMQ-PL. The criterion-related validity of the measure was also determined by examining the relationship with self-reported drug adherence using the Polish version of the Adherence to Refills and Medications Scale (ARMS) \[[@pone.0230131.ref030]\]. The surveys also included sex, age, nationality, place of residence, education and number of medications used.

For the purpose of further validation of the BMQ-PL, the following groups of patients were recruited: 1) cardiovascular inpatients, 2) cardiovascular outpatients and 3) medical students who report chronic medicines use.

1\) Cardiovascular inpatients were recruited on admission to the clinical wards of Department of Angiology, Hypertension and Diabetology, as well as Department and Clinic of Internal and Occupational Diseases and Hypertension, Wroclaw Medical University, Poland. A medical doctor assessed whether a patient meets inclusion or exclusion criteria (see below) and a qualified nurse (the same across the whole study, who was not a part of the healthcare team) introduced the assumptions of the study. Patients were informed that the hospital healthcare staff would stay blinded to the results of the questionnaires. After receiving written informed consent, the surveys were distributed. The patients were asked to complete their surveys themselves, but the nurse was available if help was needed with any questions regarding the study. Sociodemographic and clinical data was obtained from the medical records following data anonymization by attribute suppression.

Inclusion criteria were:

-   diagnosis of arterial hypertension in accordance with the current guidelines of European Society of Hypertension

-   treatment with at least 1 antihypertensive drug for 6 months or longer

-   age of 18 years or more.

Exclusion criteria were:

-   exacerbation of concurrent severe chronic diseases

-   any mental disorder confirmed with medical record

-   cognitive impairment (Mini-Mental State Examination, MMSE above 23 points)

-   inability to communicate in Polish

-   a sight defect that does not allow reading the questionnaire

-   refusal of written informed consent.

2\) Cardiovascular outpatients were recruited from universities of the third age (U3As): 2 located in Łódź and 2 in Sosnowiec. The use of such sources of participants allowed drug adherence and beliefs about medicines to be examined in non-medical settings, which could have minimized observer-expectancy bias. During a regular meeting of the members of the U3As a 10-minute introductory speech about beliefs about medicines and drug adherence was delivered, and the assumptions of the study together with inclusion and exclusion criteria (see below) were presented and discussed. The initial speech was planned to underline scientific interest in drug adherence and beliefs about medicines, without affecting the way in which the participants respond to the survey questions. After receiving written informed consent, the surveys were distributed. The respondents completed their surveys themselves, however, a researcher was available while the surveys were being completed to respond to any questions asked by study participants.

Inclusion criteria were:

-   self-reported cardiovascular disease (particularly arterial hypertension, ischemic heart disease, heart failure or arrhythmia)

-   self-reported taking of at least 1 cardiovascular drug for a year or longer

Exclusion criteria were:

-   apparent cognitive impairment (reported by study participant or researcher)

-   inability to communicate in Polish

-   a sight defect that does not allow reading the questionnaire

-   refusal of written informed consent.

3\) Medical students were recruited through the social media of Department of Pharmacology and Toxicology, Medical University of Lodz, Poland. Only medical and dental students of the third year or above were invited. The students were requested to fill out the electronic survey. In the introduction to the survey, the assumptions of the study together with inclusion and exclusion criteria (see below) were presented. Information was provided about the possibility to contact the main investigator by e-mail regarding the study. After confirming that all the inclusion criteria were met, that no exclusion criteria were met, and that electronic informed consent had been received, the survey was displayed.

Inclusion criteria were:

-   being a medical or dental student of the third year or above in the Medical University of Lodz

-   self-reported chronic use (defined as at least 90 days a year) of at least 1 medication for a year or longer (preparations used for contraceptive purpose were not defined as "medications" in this study)--the students who did not report chronic medication use were allowed to participate in the study and to complete the BMQ-General part of the questionnaire, but only the data of those meeting the criterion of chronic medication use was included into the analyses

-   age of 18 years or more.

Exclusion criteria were:

-   exacerbation of concurrent severe chronic diseases

-   inability to communicate in Polish

-   refusal of electronic informed consent.

Further adaptation of the BMQ-General for medical students {#sec015}
----------------------------------------------------------

As the factorial structure representation in the group of medical students was unsatisfactory, further steps were taken to adapt the questionnaire to this group. Firstly, a separate group of medical students were approached in the same way as described above and, following receiving informed consent, they were applied electronic survey with all the statements included in the BMQ-PL. The students were asked to attribute each *Specific* statement to the category of *Necessity*, *Concerns* or *None of the indicated* and each *General* statement to the category of *Overuse*, *Harm* or *None of the indicated*. Following this, 6 medical students or young medical doctors were interviewed in a semi-structured way regarding the understanding of each of the BMQ item according to general guidelines \[[@pone.0230131.ref027]\] and a protocol for questionnaire pretesting \[[@pone.0230131.ref028]\]. Thirdly, the newly proposed item composition of BMQ-PL-General-Med scale was applied to the data of medical students taking drugs chronically. Fourthly, the BMQ-PL-General-Med item composition was externally validated in the group of medical students who did not report chronic medication use (see above).

Data analysis {#sec016}
-------------

Missing data accounted for 0.77% of the analyzed database and was handled with pairwise deletion. Descriptive statistics included means and standard deviations (SD) or absolute and relative frequencies, if not stated otherwise. Confirmatory factor analysis (CFA) was used to determine the extent to which the obtained data fits into the assumed structure of the BMQ and multiple fit indices were estimated. Multi-group confirmatory factor analysis (MGCFA) was performed to test measurement invariance between the groups of patients \[[@pone.0230131.ref031]\]: configural, metric, scalar and residual variance invariance were successively tested by increasing levels of group equality constraints imposed on factor loadings, item intercepts and residual variances. The analyses were performed separately for each pair of the tested groups: cardiovascular inpatients vs. outpatients, cardiovascular inpatients vs. medical students, and cardiovascular outpatients vs. medical students. A χ^2^ difference test was used to compare the hierarchical models. Exploratory factor analysis (EFA) was used to further analyze the individual performance of observed variables in predicting latent variables. Cronbach's alpha and McDonald's omega were used to estimate scale internal consistency. Although the Likert scale data used in the questionnaires should be perceived as ordinal variables, the associations between the examined constructs were assessed with Pearson correlation coefficient (r) and were further explored with general linear modeling (GLM), i.e. parametric tests. This was to allow for multivariate modeling. However, corresponding equivalent non-parametric tests were performed where possible. Testing multiple hypotheses was not a subject for significance level correction because of the explorative and preliminary nature of the research. *P*-values were presented with 2 significant figures and rounded to a maximum of 4 decimal places. *P*-values below 0.05 were considered statistically significant. The analysis was performed using STATISTICA 13.1 Software (StatSoft, Tulsa, OK, USA). The raw data underlying the process of BMQ validation was deposited in Mendeley Data repository (<https://doi.org/10.17632/rvxcb9p2md.1>).

Results {#sec017}
=======

Understanding and readability of the BMQ-PL {#sec018}
-------------------------------------------

The Polish version of BMQ was proposed as a result of the original BMQ forward translation and its thorough review. Back-translation of the BMQ-PL identified minor semantic differences from the original questionnaire. The results of the semi-structured interviews of 6 elderly patients indicated that the BMQ-PL is understood as assumed by the investigators, and no such modifications in questionnaire content were needed. However, the interview identified a few misconceptions of the BMQ-PL content, which helped explain the phenomena revealed by the further quantitative analysis (see [S1 File](#pone.0230131.s001){ref-type="supplementary-material"}).

The next electronic structured interview of 14 respondents indicated that the mean score for understanding and readability of each item was more than 4 (on the 5-point Likert scale). Analysis of the BMQ-PL with the *Jasnopis* tool graded the questionnaire difficulty as 3 out of 7, which is interpreted by the tool as \"easy text, understandable to an average Pole". A sentence-by-sentence comparison of the original BMQ, BMQ-PL, and its back translation as well as the estimates of understanding and readability, is presented in [Table 1](#pone.0230131.t001){ref-type="table"}.

10.1371/journal.pone.0230131.t001

###### Comparison of the original, Polish, and back-translated version of the BMQ.

Understanding and readability were estimated using a 5-point Likert scale with anchors of "not at all" (1) to "very much" (5).

![](pone.0230131.t001){#pone.0230131.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No                                                                                                    Original                                                                                                             Polish                                                                                                                      Back-translated                                                                                Difference                                                                                                                                                                                                                                                                                                   Understanding[\*](#t001fn001){ref-type="table-fn"} (mean ± SD)   Readability[\*\*](#t001fn002){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      (mean ± SD)
  ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------- -----------------------------------------------------
  Questionnaire title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                        Beliefs about medicines questionnaire                                                                                *Kwestionariusz Przekonań na temat Leków*                                                                                   Questionnaire on opinion on drugs                                                              No significant difference                                                                                                                                                                                                                                                                                    N/A                                                              N/A

  Specific scale--introduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                        Your views about medicines prescribed for you.                                                                       *Twoje poglądy o stosowanych przez Ciebie lekach*                                                                           Your opinion on drugs that you were administered.                                              No significant difference                                                                                                                                                                                                                                                                                    N/A                                                              N/A

  We would like to ask you about your personal views about medicines prescribed for you.                *Chcielibyśmy zapytać Cię o Twoje osobiste poglądy na temat stosowanych przez Ciebie leków*.                         We would like you to give us your personal opinion on drugs that you are administered.                                      No significant difference                                                                      N/A                                                                                                                                                                                                                                                                                                          N/A                                                              

  These are statements other people have made about their medicines.                                    *Poniżej znajdują się stwierdzenia innych ludzi na temat leków*, *które stosują*.                                    Below, there are other people's opinions on drugs that they are administered.                                               No significant difference                                                                      N/A                                                                                                                                                                                                                                                                                                          N/A                                                              

  Please indicate the extent to which you agree or disagree with them by ticking the appropriate box.   *Proszę*, *wskaż*, *w jakim stopniu zgadzasz się z tymi stwierdzeniami stawiając krzyżyk w odpowiednim kwadracie*.   Please, state how much you agree on these opinions by putting a tick in the appropriate box.                                No significant difference                                                                      N/A                                                                                                                                                                                                                                                                                                          N/A                                                              

  There are no right or wrong answers. We are interested in your personal views.                        *Nie ma dobrych ani złych odpowiedzi*. *Jesteśmy zainteresowani Twoimi własnymi poglądami*.                          There are neither good nor bad opinions. We are interested in your personal opinions.                                       No significant difference                                                                      N/A                                                                                                                                                                                                                                                                                                          N/A                                                              

  Rating scale labels                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                        strongly agree, agree, uncertain, disagree, strongly disagree                                                        *zdecydowanie zgadzam się*, *zgadzam się*, *nie jestem pewien / pewna*, *nie zgadzam się*, *zdecydowanie nie zgadzam się*   I completely agree, I agree, I am not sure, I disagree, I completely disagree                  No significant difference                                                                                                                                                                                                                                                                                    N/A                                                              N/A

  Specific statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  S1                                                                                                    My health, at present, depends on my medicines.                                                                      *Moje zdrowie zależy obecnie od leków*, *które przyjmuję*.                                                                  My health currently depends on the medications I take.                                         No significant difference                                                                                                                                                                                                                                                                                    4.64 ± 0.84                                                      4.79 ± 0.58

  S2                                                                                                    Having to take these medicines worries me.                                                                           *Martwi mnie*, *że muszę przyjmować te leki*.                                                                               I am worried that I have to take these medications.                                            No significant difference                                                                                                                                                                                                                                                                                    4.71 ± 0.83                                                      4.93 ± 0.27

  S3                                                                                                    My life would be impossible without my medicines.                                                                    *Moje życie byłoby niemożliwe bez leków*.                                                                                   My life would be impossible without medication.                                                Lack of a second \"my\" makes the back-translation less personal. Polish language does not use possessive adjectives so much.                                                                                                                                                                                4.57 ± 0.94                                                      4.79 ± 0.58

  S4                                                                                                    Without my medicines I would be very ill.                                                                            *Bez moich leków byłbym bardzo chory / byłabym bardzo chora*.                                                               Without my medication I would be very sick.                                                    Back-translation is slightly less formal. In Polish language does not clearly distinguish \"ill\" and \"sick\".                                                                                                                                                                                              4.71 ± 0.73                                                      4.93 ± 0.27

  S5                                                                                                    I sometimes worry about long-term effects of my medicines.                                                           *Czasami martwię się*, *jakie mogą być długofalowe skutki działania moich leków*.                                           Sometimes I worry about the long-term effects of my medications.                               No significant difference                                                                                                                                                                                                                                                                                    4.93 ± 0.27                                                      4.79 ± 0.80

  S6                                                                                                    My medicines are a mystery to me.                                                                                    *Moje leki są dla mnie zagadką*.                                                                                            My medication is a mystery to me.                                                              No significant difference                                                                                                                                                                                                                                                                                    4.43 ± 0.85                                                      4.71 ± 0.47

  S7                                                                                                    My health in the future will depend on my medicines.                                                                 *W przyszłości stan mojego zdrowia będzie zależał od leków*.                                                                In the future, my health will depend on medicines.                                             No significant difference                                                                                                                                                                                                                                                                                    4.86 ± 0.36                                                      4.79 ± 0.43

  S8                                                                                                    My medicines disrupt my life.                                                                                        *Leki*, *które przyjmuję*, *zakłócają moje życie*.                                                                          The medication I\'m taking interferes with my life.                                            No significant difference                                                                                                                                                                                                                                                                                    4.50 ± 1.09                                                      4.36 ± 1.08

  S9                                                                                                    I sometimes worry about becoming too dependent on my medicines.                                                      *Czasami martwię się*, *że mogę za bardzo uzależnić się od leków*.                                                          Sometimes I worry that I may be too dependent on my medications.                               Back-translation refers to the present whereas an original sentence to the future.                                                                                                                                                                                                                           4.64 ± 0.50                                                      4.79 ± 0.43

  S10                                                                                                   My medicines protect me from becoming worse.                                                                         *Leki chronią mnie przed pogorszeniem stanu zdrowia*.                                                                       Medicine prevents my health from deteriorating.                                                Back-translation is less specific about the medicines.                                                                                                                                                                                                                                                       4.57 ± 0.85                                                      4.93 ± 0.27

  General scale--introduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                        Your views about medicines in general                                                                                *Twoje poglądy o lekach w ogóle*                                                                                            Your general opinion on drugs                                                                  Polish equivalent of "medicines" used in the questionnaire has no double meaning as "drugs".                                                                                                                                                                                                                 N/A                                                              N/A

  We would like to ask you about your personal views about medicines in general.                        *Chcielibyśmy zapytać Cię o Twoje osobiste poglądy na temat leków*.                                                  We would like you to give us your personal opinion on drugs.                                                                Polish equivalent of "medicines" used in the questionnaire has no double meaning as "drugs".   N/A                                                                                                                                                                                                                                                                                                          N/A                                                              

  These are statements other people have made about medicines in general.                               *Poniżej znajdują się stwierdzenia innych ludzi na temat leków*.                                                     Below, there are other people's general opinions on drugs.                                                                  Polish equivalent of "medicines" used in the questionnaire has no double meaning as "drugs".   N/A                                                                                                                                                                                                                                                                                                          N/A                                                              

  Please indicate the extent to which you agree or disagree with them by ticking the appropriate box.   *Proszę*, *wskaż*, *w jakim stopniu zgadzasz się z tymi stwierdzeniami stawiając krzyżyk w odpowiednim kwadracie*.   Please, state how much you agree on these opinions by putting a tick in the appropriate box.                                No significant difference                                                                      N/A                                                                                                                                                                                                                                                                                                          N/A                                                              

  There are no right or wrong answers. We are interested in your personal views.                        *Nie ma dobrych ani złych odpowiedzi*. *Jesteśmy zainteresowani Twoimi własnymi poglądami*.                          There are neither good nor bad opinions. We are interested in your personal opinions.                                       No significant difference                                                                      N/A                                                                                                                                                                                                                                                                                                          N/A                                                              

  Rating scale labels                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                        strongly agree, agree, uncertain, disagree, strongly disagree                                                        *zdecydowanie zgadzam się*, *zgadzam się*, *nie jestem pewien / pewna*, *nie zgadzam się*, *zdecydowanie nie zgadzam się*   I completely agree, I agree, I am not sure, I disagree, I completely disagree                  No significant difference                                                                                                                                                                                                                                                                                    N/A                                                              N/A

  General---statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  G1                                                                                                    Doctors use too many medicines.                                                                                      *Lekarze przepisują zbyt wiele leków*.                                                                                      Doctors prescribe too many drugs.                                                              The verb \"prescribe\" instead of \"use\" clarifies what the doctors do with the medicines. In fact, such a meaning is suggested in the paper describing the development of the tool \[[@pone.0230131.ref019]\] and all the Scandinavian versions have also replaced this verb \[[@pone.0230131.ref026]\].   4.50 ± 0.65                                                      4.79 ± 0.43

  G2                                                                                                    People who take medicines should stop their treatment for a while every now and again.                               *Osoby przyjmujące leki powinny od czasu do czasu robić przerwy w ich stosowaniu*.                                          People taking medicine should stop doing so from time to time.                                 No significant difference                                                                                                                                                                                                                                                                                    4.29 ±1.07                                                       4.71 ± 0.47

  G3                                                                                                    Most medicines are addictive.                                                                                        *Większość leków uzależnia*.                                                                                                Most medicines are addictive.                                                                  No difference                                                                                                                                                                                                                                                                                                4.79 ± 0.43                                                      4.93 ± 0.27

  G4                                                                                                    Natural remedies are safer than medicines.                                                                           *Naturalne środki lecznicze są bezpieczniejsze niż leki*.                                                                   Natural remedies are safer than medicine.                                                      No significant difference                                                                                                                                                                                                                                                                                    4.93 ± 0.27                                                      5.00 ± 0.00

  G5                                                                                                    Medicines do more harm than good.                                                                                    *Leki powodują więcej szkody niż pożytku*.                                                                                  Medications cause more harm than good.                                                         No significant difference                                                                                                                                                                                                                                                                                    4.79 ± 0.58                                                      4.86 ± 0.36

  G6                                                                                                    All medicines are poisons.                                                                                           *Wszystkie leki to trucizny*.                                                                                               All medicines are poisons.                                                                     No difference                                                                                                                                                                                                                                                                                                4.64 ± 0.84                                                      4.64 ± 0.84

  G7                                                                                                    Doctors place too much trust on medicines.                                                                           *Lekarze za bardzo polegają na lekach*.                                                                                     Doctors rely too heavily on medications.                                                       No significant difference                                                                                                                                                                                                                                                                                    4.71 ± 0.61                                                      4.93 ± 0.27

  G8                                                                                                    If doctors had more time with patients they would prescribe fewer medicines.                                         *Gdyby lekarze poświęcali więcej czasu pacjentom*, *przepisywaliby mniej leków*.                                            If doctors spent more time with patients, they would prescribe fewer medications.              The verb \"spend\" instead of \"have time\" implies that it is a doctor\'s decision to have more time with patients, but not e.g. a problem with health care system functioning. A French versions has also a similar verb \[[@pone.0230131.ref025]\].                                                       4.79 ± 0.43                                                      4.86 ± 0.36
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* being unambiguous and raising no doubts.

\*\* being easy and enjoyable to read.

SD--standard deviation.

N/A--not applicable.

S1-10 --subsequent *Specific* items, G1-8 --subsequent *General* items.

Study participants in the further validation process {#sec019}
----------------------------------------------------

Out of 165 cardiovascular inpatients invited to the study, 36 did not meet the inclusion criteria (31 because of an unacceptably low MMSE score), and a further 16 declined to participate in the study (12 because of unwillingness to fill the survey). In total, 113 surveys were distributed; however, 6 people resigned from participation in the study at this step, and 5 surveys were excluded due to being incorrectly filled. Hence, 102 surveys of cardiovascular inpatients were included to the study (drop-out rate of 9.7%).

Out of 157 attendees of the U3As invited to the study, 32 (20.4%) declared not using any cardiovascular medication for a year or longer, and further 17 declined to participate in the study. Of the 108 surveys distributed, 6 were found to be incorrectly completed and were excluded. Hence, 102 surveys of cardiovascular outpatients were included to the study (drop-out rate of 5.6%).

Out of 403 medical and dental students of the third year or above, who gave electronic informed consent, 40 (9.9%) reported not using medications at all, and 256 (63.5%) reported using medications from time to time, but no more than 90 days a year. A total of 107 out of 403 students (26.6%) reported using medications chronically (at least 90 days a year) and their responses were included to the analyses. Among these 107 students, 42 (39.3%) reported using anti-allergic medications, 30 (28.0%)--analgesics, 26 (24.3%)--hormonal medications, 16 (15.0%)--antibiotics, 14 (13.1%)--psychotropic medications, 13 (12.1%)--pulmonologic medications, 11 (10.3%)--cardiologic medications and 4 (3.7%)--diabetes medications.

The number of respondents in each group was satisfactory based on the recommendations regarding sample size. A minimum of hundred is advised to be sufficient to allow convergence of fit indices \[[@pone.0230131.ref032]\]. This number is also consistent with the computed sample size: as the root mean square error of approximation (RMSEA) in the population was 0.08, the RMSEA of the null hypothesis was 0.05, significance level was 0.05 and 129 degrees of freedom were used according to the model identification criteria, a sample size of 112 was needed in the study to reach a power of 0.8.

The basic sociodemographic characteristics of the study participants are presented in [Table 2](#pone.0230131.t002){ref-type="table"}.

10.1371/journal.pone.0230131.t002

###### Basic sociodemographic characteristics of the study participants.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                    Number (frequency) or mean (standard deviation)                   
  --------------------------------------------------------------------------- ------------------------------------------------- --------------- -----------------------------------------------------
  Sex                                                                                                                                           

  Male                                                                        45 (44.1%)                                        15 (14.7%)      31 (29.0%)

  Female                                                                      57 (55.9%)                                        87 (85.3%)      76 (71.0%)

  Age[\*](#t002fn001){ref-type="table-fn"}                                                                                                      

  \[years\]                                                                   63.2 (14.3) range: 20--98                         73.1 (7.4)\     23.0 (1.4)\
                                                                                                                                range: 55--89   range: 22--29

  Nationality                                                                                                                                   

  Polish                                                                      102 (100%)                                        102 (100%)      107 (100%)

  other                                                                       0 (0%)                                            0 (0%)          0 (0%)

  Place of residence                                                                                                                            

  \< 5,000 inhabitants                                                        21 (20.6%)                                        3 (2.9%)        23 (21.5%)

  5,000--50,000 inhabitants                                                   21 (20.6%)                                        15 (14.7%)      29 (27.1%)

  50,000--500,000 inhabitants                                                 15 (14.7%)                                        19 (18.6%)      28 (26.2%)

  \> 500,000 inhabitants                                                      45 (44.1%)                                        65 (63.7%)      27 (25.2%)

  Education[\*\*](#t002fn002){ref-type="table-fn"}                                                                                              

  Primary                                                                     5 (5.0%)                                          10 (10.0%)      0 (0%)

  Secondary                                                                   69 (68.3%)                                        53 (53.0%)      105 (98.1%)

  Higher                                                                      27 (26.7%)                                        37 (37.0%)      2 (1.9%)

  How many medications do you use?[\*\*\*](#t002fn003){ref-type="table-fn"}                                                                     

  1                                                                           4 (4.6%)                                          32 (31.4%)      42 (39.3%)

  2                                                                           10 (11.5%)                                        30 (29.4%)      38 (35.5%)

  3                                                                           19 (21.8%)                                        16 (15.7%)      18 (16.8%)

  4                                                                           21 (24.1%)                                        18 (17.6%)      9 (8.4%)[\*\*\*\*](#t002fn004){ref-type="table-fn"}

  5 or more                                                                   33 (37.9%)                                        6 (5.9%)        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* In the group of outpatients n = 96.

\*\* In the group of inpatients n = 101, and outpatients n = 100.

\*\*\* In the group of inpatients n = 87. In this group the number of medications used refers to the time before hospitalization.

\*\*\*\* "4 medications or more"--the question in the group of medical students did not include the option "5 or more".

The proportion of males to females varied significantly across the groups of participants (χ^2^(2) = 21.3, *p*\<0.0001).

Comparisons of the models {#sec020}
-------------------------

Four models were compared in each of the groups of patients to assess the degree of data-to-model fit: 1-factor model (all items loading 1 dimension), 2-factor model (distinguishing *Specific* and *General* dimensions), 3-factor model (distinguishing *Specific-Necessity*, *Specific-Concerns* and *General* dimensions), and 4-factor model (the original model consisting of *Specific-Necessity*, *Specific-Concerns*, *General-Overuse* and *General-Harm* dimensions).

As expected, the 2-factor model exhibited a more acceptable model fit than the 1-factor model (Δχ^2^(1) = 98.5, *p*\<0.0001 for inpatients, Δχ^2^(1) = 60.8, *p*\<0.0001 for outpatients, and Δχ^2^(1) = 100.7, *p*\<0.0001 for medical students), and the 3-factor model exhibited a more acceptable model fit than the 2-factor model (Δχ^2^(2) = 99.8, *p*\<0.0001 for inpatients, Δχ^2^(2) = 73.6, *p*\<0.0001 for outpatients, and Δχ^2^(2) = 65.5, *p*\<0.0001 for medical students). Interestingly, the original 4-factor model fit was slightly more favorable than that of the 3-factor model only in the group of medical students (Δχ^2^(3) = 14.7, *p* = 0.0021), but not in either inpatients (Δχ^2^(3) = 4.7, *p* = 0.20) or outpatients (Δχ^2^(3) = 5.9, *p* = 0.12). Moreover, Parsimony-corrected Comparative Fit Index as well as Akaike's and Bayesian Information Criteria ([Table 3](#pone.0230131.t003){ref-type="table"}) favored the simpler, 3-factor model, over the original 4-factor model for both inpatients and outpatients. The differences between discussed indices were so slight, however, that they could potentially disappear with follow-up study. Moreover, the majority of the cross-cultural BMQ validation literature supports the use of the 4-factor model; this is also the case for German and Czech languages, which are spoken in countries bordering Poland and culturally similar to Poland. As no solid evidence can be found against using the two-dimensional *General* beliefs about medicines represented by Polish people, the original 4-factor model of the BMQ-PL was preserved.

10.1371/journal.pone.0230131.t003

###### Confirmatory factor analysis model fit parameters for 1-, 2-, 3-, and 4-factor models.
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  Model            Group of patients                             
  ---------------- ---------------------- ---------------------- ----------------------
  1-factor model                                                 
  χ^2^ (df)        384.7 (135)            332.2 (135)            398.2 (135)
  *P*-value        \<0.0001               \<0.0001               \<0.0001
  χ^2^/df          2.85                   2.46                   2.95
  RMSEA (90% CI)   0.164 (0.149--0.180)   0.142 (0.126--0.158)   0.163 (0.148--0.179)
  TLI              0.427                  0.464                  0.319
  CFI/PCFI         0.495 / 0.358          0.529 / 0.369          0.400 / 0.288
  AIC / BIC        4.52 / 5.46            4.26 / 5.23            4.52 / 5.44
  SRMR             0.135                  0.140                  0.157
  2-factor model                                                 
  χ^2^ (df)        286.2 (134)            271.4 (134)            297.5 (134)
  *P*-value        \<0.0001               \<0.0001               2.22
  χ^2^/df          2.14                   2.03                   \<0.0001
  RMSEA (90% CI)   0.114 (0.098--0.131)   0.114 (0.096--0.131)   0.122 (0.106--0.138)
  TLI              0.647                  0.623                  0.572
  CFI/PCFI         0.692 / 0.489          0.672 / 0.460          0.627 / 0.435
  AIC / BIC        3.57 / 4.53            3.64 / 4.64            3.57 / 4.52
  SRMR             0.143                  0.147                  0.129
  3-factor model                                                 
  χ^2^ (df)        186.4 (132)            197.8 (132)            232.0 (132)
  *P*-value        0.0013                 0.0002                 \<0.0001
  χ^2^/df          1.41                   1.50                   1.76
  RMSEA (90% CI)   0.054 (0.027--0.076)   0.070 (0.047--0.090)   0.091 (0.073--0.108)
  TLI              0.870                  0.815                  0.733
  CFI/PCFI         0.890 / 0.615          0.843 / 0.564          0.772 / 0.524
  AIC / BIC        2.62 / 3.63            2.90 / 3.96            2.98 / 3.98
  SRMR             0.079                  0.091                  0.096
  4-factor model                                                 
  χ^2^ (df)        181.7 (129)            191.9 (129)            217.3 (129)
  *P*-value        0.0016                 0.0003                 \<0.0001
  χ^2^/df          1.41                   1.49                   1.68
  RMSEA (90% CI)   0.055 (0.027--0.077)   0.067 (0.044--0.088)   0.082 (0.063--0.100)
  TLI              0.871                  0.819                  0.759
  CFI/PCFI         0.894 / 0.607          0.850 / 0.560          0.799 / 0.533
  AIC / BIC        2.63 / 3.72            2.90 / 4.04            2.90 / 3.97
  SRMR             0.079                  0.090                  0.093

χ^2^ --chi-square statistics.

df--degrees of freedom.

CI--confidence intervals.

RMSEA--Root Mean Square Error of Approximation. The strict cut-off point estimate close to 0.06 with a lower 90% CI limit close to 0 and the upper limit less than 0.08 is currently considered "a good fit". In the past, however, the recommendations were less strict: a point estimate below 0.08 was considered "a good fit", whereas between 0.08 to 0.10 "a mediocre fit".

TLI--Tucker-Lewis index or Non-Normed Fit Index. Values at least 0.95 are preferred, but values as low as 0.80 were also acceptable.

CFI--Comparative Fit Index. Values at least 0.95 are presently recognized as indicative of "a good fit", but the limit of 0.90 was proposed in the past.

PCFI--Parsimony-corrected Comparative Fit Index. While no threshold levels have been recommended for parsimony-corrected indices, it is suggested that the values of at least 0.50 or, even better, 0.60 should be obtained.

AIC--Akaike's Information Criterion.

BIC--Bayesian Information Criterion. Both AIC and BIC are used for assessment relative to other models. The smaller the values, the better and more parsimonious the model fit.

SRMR--standardized root mean square residual. Values less than 0.05 represent "a good fit", however, values as high as 0.08 are deemed "acceptable".

The above recommendations for the model fit indices were reported in Hooper et al. \[[@pone.0230131.ref033]\].

The fit indices of 4-factor model for the group of inpatients were satisfactory. The group of outpatients presented slightly worse model fit, not meeting conventional fit criteria. The model fit for the group of medical students was far from conventional fit criteria. The comparisons of the models and their fit indices are presented in the [Table 3](#pone.0230131.t003){ref-type="table"}. The results of the 4-factor model confirmatory factor analysis are presented in [Fig 2](#pone.0230131.g002){ref-type="fig"}.

![Confirmatory factor analysis of the 4-factor model of the BMQ-PL.\
The numerical values represent lambda coefficients of the indicators for the groups of Inpatients / Outpatients / Students. The *p*-values for the significance of the parameters are \<0.0001, if not stated otherwise: \**p* = 0.0001--0.001, \*\**p* = 0.001--0.01, \*\*\**p* = 0.01--0.05, lambda coefficients presented in grey are non-significant (*p*≥0.05). SN--*Specific-Necessity* subscale, SC--*Specific-Concerns* subscale, GO--*General-Overuse* subscale, GH--*General-Harm* subscale, S1-10 --subsequent *Specific* items, G1-8 --subsequent *General* items, e--latent unobserved error related to the measurement.](pone.0230131.g002){#pone.0230131.g002}

Measurement invariance between the groups of patients {#sec021}
-----------------------------------------------------

To further explore equivalency of the 4-factor BMQ model between the groups of patients, MGCFA analysis was performed. The detailed results of the MGCFA are presented in [S2 File](#pone.0230131.s002){ref-type="supplementary-material"}. The results are briefly discussed below.

1\) Configural invariance was tested to assess whether the different groups of participants conceptualize the constructs in the same way. The comparison of in- and outpatients gives a model with the fit indices slightly worse than conventional cut-off criteria. Hence, the characteristics of both groups of cardiovascular patients appear somewhat different. On the other hand, medical students may employ a substantially different mode of construct conceptualization than the two groups of cardiovascular patients. For the purpose of this study, however, further steps of measurement invariance testing were performed in all pairs of comparisons.

2\) Metric invariance was tested to assess whether the different groups of participants respond to the items in the same way, attributing them the same meaning. The criteria for metric invariance was met only for the comparison of in- and outpatients, and for outpatients vs. medical students. The full metric invariance test of cardiovascular inpatients vs. medical students failed, but the criteria for partial metric invariance between these groups were met for the *Specific-Concerns* and *General-Harm* subscales, both considering negative attributes of medicines.

3\) Scalar invariance was tested to assess whether the different groups of participants have the same basal level of observed variables (intercepts). Testing full scalar invariance resulted in the rejection of the hypothesis of scalar invariance across all the groups. However, the criteria for partial scalar invariance were met for *Specific-Necessity* and *General-Overuse* subscales for the comparison of in- and outpatients: both these subscales consider use and overuse of medicines. The results suggest that the basal level of responses displayed by the groups of respondents significantly depends on their social and clinical state.

4\) Residual variance invariance was tested to assess whether the different groups of participants present the same level of unexplained variance in responses to the items. This type of invariance was established only for the pair of groups, which presented at least partial scalar invariance, i.e. cardiovascular in- and outpatients. The test implies that the residual variance is not invariant between these groups, apart from the *Specific-Concerns* subscale. This suggests the confounders play important differential role in the way how the participants respond to the items.

Internal consistency and other psychometric properties {#sec022}
------------------------------------------------------

Internal consistency estimates, measured as Cronbach's alpha, were acceptable (≥0.7) \[[@pone.0230131.ref034]\] for the *Specific-Necessity* subscale in all groups, as well as for *Specific-Concerns* in inpatients and *General-Overuse* in outpatients. The other Cronbach's alpha values were questionable (≥0.6) with the *General-Harm* subscale in medical students being particularly low. On the other hand, McDonald's omega estimates of internal consistency were good in all groups ([Table 4](#pone.0230131.t004){ref-type="table"}).

10.1371/journal.pone.0230131.t004

###### Internal consistency of the BMQ subscales.
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  Internal consistency measures   Group of patients                    
  ------------------------------- ---------------------- ------ ------ ------
  Cronbach's alpha                *Specific-Necessity*   0.82   0.79   0.82
  *Specific-Concerns*             0.70                   0.65   0.66   
  *General-Overuse*               0.66                   0.70   0.66   
  *General-Harm*                  0.64                   0.65   0.42   
  McDonald's omega                0.91                   0.91   0.90   

In order to further analyze the extent to which the individual item participates in latent variable determination, item discrimination (measured as a corrected item-total correlation with assumed scales) was calculated. Great majority of the item discrimination values were at least 0.2, indicating adequate loading of the latent variables. The mean values for the response to each item were close to 3, the middle value in the BMQ 5-point Likert scale. The dispersion of the responses were adequate ([Table 5](#pone.0230131.t005){ref-type="table"}).

10.1371/journal.pone.0230131.t005

###### Basic psychometric characteristics of the BMQ-PL items.
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  Subscale / / Item            Group of patients                                           
  ---------------------------- ------------------- ------------ ------ ------------ ------ ------------
  *Specific-Necessity*                             19.9 (3.0)          19.1 (3.8)          16.2 (5.2)
  S1                           0.62                4.1 (0.8)    0.56   3.9 (1.1)    0.64   3.6 (1.3)
  S3                           0.65                3.8 (0.9)    0.57   3.6 (1.1)    0.52   2.4 (1.4)
  S4                           0.80                4.0 (0.8)    0.63   3.7 (1.0)    0.75   2.8 (1.5)
  S7                           0.39                3.8 (0.8)    0.55   3.8 (1.0)    0.57   3.4 (1.3)
  S10                          0.67                4.2 (0.7)    0.53   4.2 (0.9)    0.62   4.0 (1.2)
  *Specific-Concerns*                              15.7 (3.6)          14.2 (3.9)          10.9 (3.7)
  S2                           0.40                3.6 (1.1)    0.39   3.1 (1.3)    0.42   3.2 (1.4)
  S5                           0.54                3.6 (0.9)    0.40   3.4 (1.0)    0.48   3.2 (1.4)
  S6                           0.39                2.8 (1.1)    0.32   2.7 (1.2)    0.35   1.4 (0.7)
  S8                           0.50                2.9 (1.1)    0.42   2.3 (1.2)    0.43   1.5 (0.8)
  S9                           0.45                2.9 (1.1)    0.49   2.7 (1.3)    0.49   1.7 (1.1)
  *Necessity-minus-Concerns*                       4.2 (4.6)           5.1 (5.2)           5.3 (5.8)
  *General-Overuse*                                13.0 (2.8)          12.9 (3.6)          12.2 (3.5)
  G1                           0.45                3.2 (1.1)    0.34   2.9 (1.3)    0.45   3.3 (1.2)
  G4                           0.31                3.1 (0.9)    0.40   3.1 (1.2)    0.20   2.7 (1.2)
  G7                           0.51                3.1 (1.0)    0.61   3.2 (1.2)    0.65   2.7 (1.3)
  G8                           0.48                3.5 (1.0)    0.61   3.7 (1.3)    0.52   3.4 (1.3)
  *General-Harm*                                   11.1 (2.6)          10.1 (3.1)          7.3 (2.7)
  G2                           0.49                2.9 (1.0)    0.37   2.9 (1.2)    0.24   2.0 (1.2)
  G3                           0.35                3.1 (1.0)    0.42   3.0 (1.1)    0.32   1.9 (1.1)
  G5                           0.55                2.6 (0.8)    0.51   2.0 (0.9)    0.36   1.5 (0.8)
  G6                           0.32                2.5 (0.9)    0.43   2.2 (1.2)    0.09   1.9 (1.3)

SD--standard deviation.

S1-10 --subsequent *Specific* items, G1-8 --subsequent *General* items.

Rating scale labels: strongly agree-- 5, agree-- 4, uncertain-- 3, disagree-- 2, strongly disagree-- 1.

Exploratory factor analysis was used in further analysis of the construct representation by the items. The analysis was performed in each group of patients separately for *Specific* and *General* scales. The number of factors in the analyses was rigidly fixed as 2 for *Specific* and 2 for *General* scales in order to reflect the assumed structure of the constructs. In fact, such a number of extracted factors was consistent with the scree-plot and the eigenvalue-more-than-one criterion. The extracted factors could represent slightly more than 50% of data variability. The analysis indicated that the items representing the *Specific* facets of beliefs have adequate primary factor loadings with almost no substantial cross-loadings. On the other hand, the factor loadings of majority of items representing *General* facets of beliefs were diverse, not clearly indicating whether the particular item maps *Overuse* or *Harm* subscale ([Table 6](#pone.0230131.t006){ref-type="table"}).

10.1371/journal.pone.0230131.t006

###### Results of exploratory factor analysis performed in each scale separately.

a\) *Specific* scale, b) *General* scale. The factor differentiation was achieved by raw varimax factor rotation. The expected loadings are presented in bold on a dark-grey background, with substantial cross-loadings on a light-grey background.

![](pone.0230131.t006){#pone.0230131.t006g}

                            Group of patients                                                                                                                          
  ------------------------- --------------------- -------------------------------------- --------------------- ---------------------- --------------------- ---------- ----------
  **a) *Specific* scale**                                                                                                                                              
  Subscale                  Item                  Factor loadings of expected subscale                                                                                 
  *Specific-Necessity*      *Specific-Concerns*   *Specific-Necessity*                   *Specific-Concerns*   *Specific-Necessity*   *Specific-Concerns*              
  *Specific-Necessity*      S1                    **0.77**                               -0.04                 **0.74**               -0.14                 **0.82**   -0.06
  S3                        **0.81**              0.03                                   **0.70**              0.05                   **0.63**              0.16       
  S4                        **0.89**              -0.01                                  **0.77**              -0.02                  **0.84**              0.16       
  S7                        **0.55**              0.09                                   **0.71**              0.26                   **0.71**              -0.00      
  S10                       **0.81**              -0.03                                  **0.72**              -0.09                  **0.79**              -0.10      
  *Specific-Concerns*       S2                    0.22                                   **0.63**              0.04                   **0.62**              0.43       **0.54**
  S5                        0.03                  **0.75**                               0.14                  **0.63**               -0.02                 **0.68**   
  S6                        -0.06                 **0.62**                               0.25                  **0.51**               -0.15                 **0.64**   
  S8                        -0.07                 **0.71**                               -0.14                 **0.67**               0.12                  **0.62**   
  S9                        -0.11                 **0.66**                               -0.07                 **0.76**               0.01                  **0.78**   
  Eigenvalue                3.06                  2.29                                   2.77                  2.17                   3.11                  2.22       
  Variance explained        30.6%                 22.9%                                  27.7%                 21.7%                  31.1%                 22.2%      
  **b) *General* scale**                                                                                                                                               
  Subscale                  Item                  Factor loadings                                                                                                      
  *General-Overuse*         *General-Harm*        *General-Overuse*                      *General-Harm*        *General-Overuse*      *General-Harm*                   
  *General-Overuse*         G1                    **0.79**                               -0.05                 **-0.00**              0.82                  **0.62**   0.32
  G4                        **0.20**              0.65                                   **0.74**              0.03                   **0.13**              0.62       
  G7                        **0.62**              0.26                                   **0.59**              0.52                   **0.84**              0.17       
  G8                        **0.71**              0.12                                   **0.47**              0.59                   **0.85**              -0.06      
  *General-Harm*            G2                    0.39                                   **0.64**              0.21                   **0.71**              -0.02      **0.71**
  G3                        -0.05                 **0.85**                               0.60                  **0.30**               0.17                  **0.66**   
  G5                        0.71                  **0.32**                               0.75                  **0.12**               0.13                  **0.67**   
  G6                        0.60                  **0.07**                               0.52                  **0.25**               0.50                  **0.06**   
  Eigenvalue                2.57                  1.75                                   2.36                  1.97                   2.12                  1.90       
  Variance explained        32.1%                 21.8%                                  29.5%                 24.6%                  26.5%                 23.7%      

S1-10 --subsequent *Specific* items, G1-8 --subsequent *General* items.

*Specific* scale for the group of Inpatients:

KMO = 0.721; the Bartlett's test of sphericity: χ^2^(45) = 307.2, *p*\<0.0001.

*Specific* scale for the group of Outpatients:

KMO = 0.720; the Bartlett's test of sphericity: χ^2^(45) = 218.4, *p*\<0.0001.

*Specific* scale for the group of Medical students:

KMO = 0.734; the Bartlett's test of sphericity: χ^2^(45) = 322.7, *p*\<0.0001.

*General* scale for the group of Inpatients:

KMO = 0.761; the Bartlett's test of sphericity: χ^2^(28) = 181.6, *p*\<0.0001.

*General* scale for the group of Outpatients:

KMO = 0.812; the Bartlett's test of sphericity: χ^2^(28) = 193.9, *p*\<0.0001.

*General* scale for the group of Medical students:

KMO = 0.718; the Bartlett's test of sphericity: χ^2^(28) = 145.7, *p*\<0.0001.

KMO--Kaiser-Meyer-Olkin measure of sampling adequacy.

Four latent constructs comprising beliefs about medicines were significantly inter-correlated. Particularly, *General-Overuse* with *General-Harm*, and *Specific-Concerns* with both *General* subscales. *Specific-Necessity* was found to negatively correlate with both *General* subscales only in the group of inpatients, however, its association with *General-Harm* was uncertain due to non-significant result of a non-parametric test ([Table 7](#pone.0230131.t007){ref-type="table"}).

10.1371/journal.pone.0230131.t007

###### Association between the BMQ-PL subscales.

The associations are estimated with Pearson's correlation coefficients. Statistically significant results are presented in bold. The extent of cell shading reflects the extent of correlation. Results of equivalent non-parametric tests for all the associations were presented in [S1 Table](#pone.0230131.s004){ref-type="supplementary-material"} and their similarity to parametric ones documented in [S1 Fig](#pone.0230131.s005){ref-type="supplementary-material"}.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
       Group of patients                                                                                                                                                                                                           
  ---- ----------------------------------------------------------------- ---------------------- ---------------------- ------------------ ---------------------- ---------------------- ------------------ ----------------------- ----------------------
  SC   0.01\                                                                                                           0.08\                                                            0.18 *p* = 0.071                           
       *p* = 0.89                                                                                                      *p* = 0.47                                                                                                  

  GH   **-0.28**[\*](#t007fn005){ref-type="table-fn"} ***p* = 0.0045**   **0.39 *p*\<0.0001**                          -0.09\             **0.44 *p*\<0.0001**                          -0.13 *p* = 0.18   **0.28 *p* = 0.0034**   
                                                                                                                       *p* = 0.40                                                                                                  

  GO   **-0.28 *p* = 0.0041**                                            **0.44**\              **0.53 *p*\<0.0001**   -0.09 *p* = 0.38   **0.40 *p*\<0.0001**   **0.61 *p*\<0.0001**   -0.05 *p* = 0.59   **0.31 *p* = 0.0015**   **0.45 *p*\<0.0001**
                                                                         ***p*\<0.0001**                                                                                                                                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SN--*Specific-Necessity* subscale.

SC--*Specific-Concerns* subscale.

GO--*General-Overuse* subscale.

GH--*General-Harm* subscale.

\* equivalent non-parametric Spearman's rho test yielded non-significant result (*p* = 0.088).

Criterion-related validity of the questionnaire {#sec023}
-----------------------------------------------

The criterion-related validity of the BMQ-PL questionnaire was assessed with regard to the self-reported measure of medication adherence (Polish version of the ARMS scale). It was assumed that adherence is positively associated with *Specific-Necessity*, and negatively with *Specific-Concerns* and both *General* subscales. *Necessity-minus-Concerns*, calculated as a difference between the scores of the subscales \[[@pone.0230131.ref014]\], was assumed to be the most indicative of medication adherence. In fact, the hypotheses worked well for the group of outpatients, but in the group of inpatients, the assumed association approached significance level only in the *Specific-Concerns* subscale. The adherence was not monitored in the group of medical students due to the diverse patterns of medication use in this group ([Table 8](#pone.0230131.t008){ref-type="table"} and [Fig 3](#pone.0230131.g003){ref-type="fig"}).

![Association between self-reported medication adherence and *Necessity-minus-Concerns* beliefs about medicines.\
Adherence was reported with the use of the Polish version of Adherence to Refills and Medications Scale (ARMS), and *Necessity-minus-Concerns* as a difference between the relevant *Specific* subscales of the Polish version of Beliefs about Medicines Questionnaire (BMQ-PL). The results are reported separately for Inpatients (red colored) and Outpatients (blue colored). The size of the markers represents the number of cases with the given coordinates. Quantitative analysis of the association is reported in [Table 8](#pone.0230131.t008){ref-type="table"}.](pone.0230131.g003){#pone.0230131.g003}

10.1371/journal.pone.0230131.t008

###### Association of the BMQ-PL subscales with self-reported measure of drug adherence.

Drug adherence was assessed with the use of Polish version of the Adherence to Refills and Medications Scale. Statistically significant results are presented in bold. The extent of cell shading reflects the extent of correlation. Results of equivalent non-parametric tests for the univariate associations were presented in [S1 Table](#pone.0230131.s004){ref-type="supplementary-material"} and their similarity to parametric ones documented in [S1 Fig](#pone.0230131.s005){ref-type="supplementary-material"}.

![](pone.0230131.t008){#pone.0230131.t008g}

                               Group of cardiovascular patients                                     Difference between in- and outpatients[\*\*](#t008fn002){ref-type="table-fn"}                                                                       
  ---------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------ ------------------------ ----------------- -----------------
  *Specific-Necessity*         -0.04 *p* = 0.71                                                     -0.02 *p* = 0.84                                                                **0.29 *p* = 0.0053**    0.22 *p* = 0.059         ***p* = 0.031**   *p* = 0.078
  *Specific-Concerns*          **-0.21**[\*\*\*](#t008fn003){ref-type="table-fn"} ***p* = 0.038**   **-0.24 *p* = 0.036**                                                           **-0.24 *p* = 0.024**    **-0.24 *p* = 0.021**    *p* = 0.85        *p* = 0.71
  *Necessity-minus-Concerns*   0.14 *p* = 0.18                                                      0.17 *p* = 0.13                                                                 **0.40 *p* = 0.0001**    **0.33 *p* = 0.0018**    *p* = 0.069       *p* = 0.38
  *General-Overuse*            0.08 *p* = 0.45                                                      0.10 *p* = 0.39                                                                 **-0.27 *p* = 0.0091**   **-0.27 *p* = 0.0095**   ***p* = 0.024**   ***p* = 0.049**
  *General-Harm*               -0.11 *p* = 0.27                                                     -0.11 *p* = 0.35                                                                **-0.30 *p* = 0.0030**   **-0.25 *p* = 0.015**    *p* = 0.19        *p* = 0.27

\* adjusted for age, sex, education, place of residence and number of drugs used.

\*\* General Linear Model--variables included to the model: group, BMQ subscale and their two-way interaction.

\*\*\* equivalent non-parametric Spearman's rho test yielded non-significant result (*p* = 0.063).

The number of medications used was positively correlated with the following BMQ-PL subscales (after combining patient groups): *Specific-Necessity* (r = 0.33, *p*\<0.0001), *Specific-Concerns* (r = 0.32, *p*\<0.0001), and *General-Harm* (r = 0.19, *p* = 0.0012), but not with *General-Overuse* (r = 0.01, *p* = 0.88). Results of equivalent non-parametric tests for these associations were presented in [S1 Table](#pone.0230131.s004){ref-type="supplementary-material"} and their similarity to parametric ones documented in [S1 Fig](#pone.0230131.s005){ref-type="supplementary-material"}.

Further adaptation of the BMQ-General for medically-educated respondents {#sec024}
------------------------------------------------------------------------

Following a series of qualitative and quantitative analyses, a modified version of the BMQ-PL-General was proposed, which was suitable for medically-educated respondents (BMQ-PL-General-Med). The scale consisted of all the original items except G6 (*All medicines are poisons*), grouped into a 3-item *Overuse* subscale (items G1, G7, G8) and a 4-item *Harm* subscale (items G2, G3, G4, G5). The scale exhibited good data-to-model fit, even in external validation, and satisfactory internal consistency. The details on the analyses performed and their results are reported in [S3 File](#pone.0230131.s003){ref-type="supplementary-material"}.

Discussion {#sec025}
==========

In order to accurately measure and report patient beliefs about medicines, a rigorously corroborated tool is needed \[[@pone.0230131.ref022]\]. The present study is the first to describe the Polish version of the Beliefs about Medicines Questionnaire (BMQ-PL) and provide satisfactory data for its validity. The original questionnaire was adapted to Polish with an in-depth lexical analysis. Its structure was recognized in the group of cardiovascular in- and outpatients as well as in medical students taking chronic medication.

The process of English-to-Polish translation of the original BMQ involved a few substantial modifications in the item wording. This was presented and discussed in detail in [Table 1](#pone.0230131.t001){ref-type="table"}. The decision to reword some of the items stemmed from the detailed analysis of an article describing the development of the original questionnaire \[[@pone.0230131.ref019]\], this was supported by other adaptations of the questionnaire \[[@pone.0230131.ref025], [@pone.0230131.ref026]\] and finally endorsed by the main Author of the original tool. The BMQ-PL was found to transmit a clear message in the target language and, ultimately, was acceptably well understood and readable by Polish patients. The presence of a few notions regarding the way the BMQ-PL content was understood do not undermine its appropriateness, but rather shed light on explaining the phenomena reported with quantitative analysis.

The selection of the groups of patients for the validation analysis was not accidental. Cardiovascular diseases are the number 1 cause of death globally \[[@pone.0230131.ref035]\], and cardiovascular patients represent considerable proportion of the elderly society. According to the recent report of the Central Statistical Office in Poland \[[@pone.0230131.ref036]\], 48.8% of people aged 60--69 take cardiovascular medications, whereas among people aged 70 and more, the proportion reaches as much as 72.7%. It was decided not to include the patients with other diseases to the study, as similar questionnaire structure representation and proof of validity was expected. In fact, in the original BMQ development and validation report, the factor structure exhibited an acceptable degree of stability between groups of asthmatic, diabetic, renal, cardiac, psychiatric and general medical patients, confirming its versatility \[[@pone.0230131.ref019]\]. The process of validation of the French version of the BMQ was performed in the group of patients suffering from such a diverse diseases as diabetes and AIDS, and the authors concluded that the construct manifests in the same way in each disease group \[[@pone.0230131.ref025]\]. In contrast, it was decided to compare cardiovascular patients suffering from their disease in the opposite circumstances: hospitalized patients in the day of admission, whose health may be endangered and not stable (inpatients), with the socially-active participants of U3As surveyed in non-medical settings (outpatients). In- and outpatients may not substantially differ in terms of their knowledge about the disease \[[@pone.0230131.ref037]\], but may differ in terms of disease advance, control and comorbidities \[[@pone.0230131.ref038]\], consequently representing very different groups of patients. Additionally, the group of medical students taking medications chronically (at least 90 days a year) was included into the analysis. Despite obvious differences, this group may be similar to the cardiovascular outpatients due to their shared academic background. The assessment of beliefs about medicines in medical students and healthcare professionals has already been performed \[[@pone.0230131.ref039]--[@pone.0230131.ref041]\], but only little attention was paid to ensure the validity of the tool in such a group of respondents \[[@pone.0230131.ref042]\] and to measure invariance between people with and without medical education. The current report complements these shortcomings.

The analysis presented in this study confirmed that the construct of beliefs about medicines has a 4-factor structure, identical with the original version. However, an alternative 3-factor structure, combining all the *General* beliefs, is possible as well. This is reflected also by the substantial association between the *General-Overuse* and *General-Harm* subscales in all the tested groups of patients (Pearson's r ranging from 0.45 to 0.61). Such association was replicated in many other samples tested with the BMQ: the original one (r = 0.40) \[[@pone.0230131.ref019]\], the French (r = 0.55 and r = 0.87) \[[@pone.0230131.ref025]\], the German (r = 0.49) \[[@pone.0230131.ref043]\] and the Greek language versions (r = 0.36) \[[@pone.0230131.ref044]\] suggesting that both *General* concepts might be merged and termed simply *General-Negative*. Such a proposal of 3-factor BMQ representation was reported for Spanish psychiatric outpatients \[[@pone.0230131.ref042]\]. However, there is little evidence against the 4-factor structure in the Polish cardiovascular patients, and therefore it is highly advisable to use it in further Polish research.

Some Cronbach's alpha estimates of internal consistency were below the conventional acceptable threshold \[[@pone.0230131.ref034]\]. However, as the BMQ-PL includes meaningful content and represents reasonable unidimensionality of the subscales \[[@pone.0230131.ref019]\], low internal consistency may not be a major barrier to its validity \[[@pone.0230131.ref045]\]. In fact, other BMQ validation studies have also replicated such questionable Cronbach's alpha values \[[@pone.0230131.ref019], [@pone.0230131.ref025], [@pone.0230131.ref046]\]. Cronbach's alpha is interpreted as the extent of equivalence of different sets of subscale items that give the same measurement outcomes \[[@pone.0230131.ref047]\]. Consequently, a low value suggests that different items within a subscale are not closely related to each other and may cover different facets of the same construct. It must be also noted that Cronbach's alpha may be negatively biased if certain assumptions, such as equal factor loadings of subscale items or non-correlated errors, are violated. As this may be the case in the present study, McDonald's omega values, which were adequate for the BMQ-PL, appear more robust estimators of internal consistency \[[@pone.0230131.ref034], [@pone.0230131.ref048]\].

Confirmatory factor analysis indicated a satisfactory data-to-model fit for cardiovascular inpatients, strengthening the proof of validity of the BMQ-PL in this sample. The tested factorial structure in the group of cardiovascular outpatients was less represented by the responses to the individual items, which suggests that the cognitive depiction of medications was less coherent in this group. This may result from the diversity of the group of outpatients, whose medical diagnosis, comorbidities, verified list of medications, and social situation were not confirmed with medical records, and the inclusion and exclusion criteria to participate in the study were largely self-assessed. Nevertheless, this fact does not preclude the possibility of valid use of the BMQ-PL in this group of patients.

The measurement invariance \[[@pone.0230131.ref031]\] of the construct representation was somewhat confirmed between inpatients and outpatients. Although the groups were found to conceptualize "beliefs about medicines" in slightly different way (configural non-invariance), they attributed the same meaning to individual questionnaire items (metric invariance). However, the background assessment of the observed variables constituting *Specific-Concerns* and *General-Harm* subscales appeared more negative in the group of inpatients than outpatients (scalar non-invariance). This is not surprising, as the sense of deteriorating health and the personal burden of hospitalization or polypharmacy \[[@pone.0230131.ref049]\]--as compared to relative well-being of socially active attendees of the U3A \[[@pone.0230131.ref050]\]--may intensify medication-related concerns and beliefs about their harmful effects. The residual variability of responses to majority of the items between in- and outpatients was also different (residual variance non-invariance), implying substantial impact of health and social characteristics of in- and outpatients in assessing the beliefs about medicines. One should also bear in mind that confirming configural, metric and scalar invariance is a prerequisite of a meaningful comparison of a scale scores between the tested groups \[[@pone.0230131.ref031]\]. Not meeting all these invariance criteria, no formal BMQ-PL score comparisons were performed.

The remaining psychometric properties of the scale were largely encouraging in the group of cardiovascular in- and outpatients and internal consistency was satisfactory. The mean score in each individual item was close to the middle value and the adequate dispersion was noted, suggesting the optimal use of the 5-point Likert scale and little skewness. Exploratory factor analysis together with association between the BMQ subscales, however, seem to provide confusing results. Although a 4-factor solution represented about 50% of data variability in factor analysis (as in the other reports \[[@pone.0230131.ref019], [@pone.0230131.ref043], [@pone.0230131.ref051]\]), and a clear separation of *Specific-Necessity* and *Specific-Concerns* subscales was found, the separation between *Specific* and *General* facets as well as *General-Overuse* and *General-Harm* subscales was substantially impaired. Again, the current results are not significantly different from those of previous studies. The original BMQ report \[[@pone.0230131.ref019]\] and many other BMQ language versions \[[@pone.0230131.ref043], [@pone.0230131.ref044], [@pone.0230131.ref046], [@pone.0230131.ref051]\] already indicated that *Specific* and *General* subscales are not fully separated, suggesting some overlap between *Specific-Concerns* with *General* items, which is coherent with present findings. The possible explanation of *General-Harm* and *Specific-Concerns* overlap is that the *General-Harm* beliefs about medicines may be formed from the personal experience of the patients, which is actually the representation of *Specific-Concerns* domain, as revealed by the interviews with the patients reported in this paper. The overlap between the *General-Overuse* and *General-Harm* was further illustrated by substantial association between the constructs and was discussed above. In fact, in the exploratory factor analysis, varimax rotation of the factors was used, which resulted in orthogonal factor presentation, falsely assuming no correlation between the constructs. Such a factor rotation method was also used by Mahler et al. \[[@pone.0230131.ref043]\]. It was employed to maximally differentiate the constructs, allowing compromising the quantitative interpretation of factor loading values.

The criterion-related validity of the BMQ-PL was fully confirmed in the group of cardiovascular outpatients, indicating the assumed association of beliefs about medicines with self-reported medication adherence. Stronger beliefs about the necessity of medicines was associated with better adherence, and stronger concerns and a more negative view of medicines with worse adherence. The present results support also the value of the well-defined concept of Necessity-Concerns Framework in predicting adherence \[[@pone.0230131.ref014]\]. Interestingly, such the associations were not found for the group of cardiovascular inpatients, apart from *Specific-Concerns* being negatively linked with adherence at borderline statistical significance. Some explanation for this phenomenon is provided by the residual analysis of regression modeling ([Fig 3](#pone.0230131.g003){ref-type="fig"}). For the group of inpatients, in contrast to outpatients, the distribution of residuals is far from normal, being highly left-skewed and compromising the estimate of regression parameters. This is because, in the group of inpatients, particularly those expressing lower *Necessity-minus-Concerns* beliefs, the results of self-reported adherence touched the maximum limit. Although the patients were informed that the results of the surveys (including the adherence questionnaire) will not be revealed to the healthcare practitioners, it cannot be excluded that the results are biased towards reporting more positive adherence \[[@pone.0230131.ref052]\] as a manifestation of observer-expectancy effect \[[@pone.0230131.ref053]\]. Another explanation is that a non-adherent patient may restart taking tablets (even discarding excessive ones \[[@pone.0230131.ref054]\]) in the pre-admission period (in case of planned admission) to appear to be following the regimen and report high adherence. Indeed, self-reported medication adherence measures are known to overestimate true adherence, and one factor predicting such overestimated adherence may be anxiety \[[@pone.0230131.ref052]\], which may increase in the pre-admission period \[[@pone.0230131.ref055], [@pone.0230131.ref056]\]. As a result, such false-positive pre-admission adherence may not be much influenced by individual beliefs about medicines. The association between beliefs about medicines and drug adherence may be further complicated by the significant difference in the proportions of males and females between the inpatient and outpatient groups, as both the constructs may be related to sex \[[@pone.0230131.ref057], [@pone.0230131.ref058]\]. Consequently, the results of the association adjusted to covariates should be perceived as more accurate. An adherence measure that is more sensitive and less susceptible to bias \[[@pone.0230131.ref010]\] is needed to test for belief-adherence association in a well-balanced group of patients.

Contrary to the cardiovascular patients, the factorial structure of the construct was below borderline in the group of medical students as the fit indices were poor. Measurement invariance analysis showed that medical students may conceptualize the beliefs about medicines in a different way than patients without medical education or may attribute the other meaning to the items. Internal consistency estimates were heterogeneous across the subscales, being particularly low for the *General-Harm* subscale in medical students as expressed by Cronbach's alpha. Similar low values were replicated by some other reports suggesting the *General-Harm* subscale not being coherent for some groups of patients \[[@pone.0230131.ref019], [@pone.0230131.ref046]\], but here it may result from measurement non-invariance \[[@pone.0230131.ref042]\]. In response to the unsatisfactory psychometric properties of the original BMQ-PL structure for the *General* scale in the group of medical students, the modified BMQ-PL-General scale was proposed to be used in medical students and healthcare professionals (BMQ-PL-General-Med). The great advantage of the used methodology was that it employed a mixed method approach \[[@pone.0230131.ref059]\], blending qualitative semi-structured interviews with quantitative survey and psychometric analyses. This afforded an insight into the misconceptions that medically-educated people may hold about the BMQ. According to the authors' knowledge, such results were reported for the first time. Additionally, the external validation of the model confirmed the stability and applicability of the newly proposed BMQ-PL-General-Med scale.

The present study does have some limitations that warrant mention while interpreting the results. Firstly, the groups of patients were sampled with a convenience technique. This may restrict the generalizability of the results as it resulted in significant differences in the male-female composition of the inpatient and outpatient groups. Secondly, although the other research papers validating the BMQ imply stability of the construct representation between different groups of patients, no proof regarding the validity of the BMQ-PL was provided in other than cardiovascular and medical samples. Thus, one should be cautious, while applying BMQ-PL to the other groups of patients, ideally pre-testing the questionnaire each time. Thirdly, the selection of the statements to adapt the BMQ-PL for medically-educated people was limited to the set of 8 *General* statements included in the original BMQ-PL only, hence narrowing the spectrum of possible cognitive representations of the construct. Fourthly, the criterion-related validity was assessed with a self-reported measure of drug adherence only and, taking into account incoherence of the results, more objective outcome measures should be included. Finally, one should have in mind that the BMQ-PL was not formally validated as a decision-making tool to examine individual respondents in detail. Rather, the BMQ-PL should be used as a research tool to conclude about the phenomena observed at a population level. Consequently, using it to identify beliefs about treatment in a particular patient should be done with caution.

Conclusion {#sec026}
==========

The present report provides satisfactory proof of validity of the Polish version of Beliefs about Medicines Questionnaire to be used among cardiovascular patients. The obtained results confirm the value of the BMQ for medical and social research purpose. Medically-educated people may conceptualize the beliefs about medicines in general in slightly different way than laymen, and the use of original BMQ for those medically educated is not recommended. Instead, a modified version of the BMQ-General, which appears suitable for medically educated people, is proposed. The BMQ-PL requires further validation procedures, however, the present report is conclusive and has a potential to push a research forward regarding beliefs about medicines.
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Responses to Editor and Reviewers

Below we list the responses to the Editor's and Reviewers' comments.

Editor's comments

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

We have made every effort to ensure that our manuscript meets PLOS ONE's style requirements, according to the provided template. We hope that we have included all necessary corrections.

2\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

The DOI number of the repository has been already provided (line 269 in the revised manuscript), however, it has not been activated yet. We will activate it once our manuscript is accepted for publication.

3\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

Originally we wrote: "Some explanation for this phenomenon is provided by the residual analysis of regression modeling (data not shown)."

By "data not shown" we meant "the results of the analysis were not explicitly reported". In fact, data underling this analysis will be publicly available in a data repository (should our manuscript will be accepted for publication) as stated in lines 267-269 (according to the revised manuscript), but the result of residual analysis were not explicitly reported in the manuscript. The only presentation of residual analysis is included in Figure 3.

Consequently, the phrase "data not shown" has been replaced with "(Figure 3)".

Reviewer\'s comments

Reviewer \#1: This is an overall well-planned, -conducted and -analyzed validation of a new version of an existing questionnaire. The need of an appropriate Polish instrument to measure beliefs about medicine is evident, the introduction is well-written. Moreover, it becomes clear that the authors invested a substantial amount of time and consideration into the development and testing of the questionnaire. The process of item forward- and back-translation and piloting appears appropriate. The discussion mentions potential limitations and is overall well-balanced. I have some comments / questions directed at guiding the reader to a better understanding of some analyses and their interpretations.

We thank Reviewer \#1 for the careful reading of our manuscript and for his/her constructive comments.

1\. Although the authors employ and report a variety of analyses to demonstrate the reliability and validity of their instrument, at times, their use of criteria for how to judge outcomes as "good" or "acceptable" appears a bit imprecise. For example, to my knowledge, a scale has an acceptable consistency with a minimal Cronbach alpha of .7. However, the authors call internal consistency as "satisfactory (\>0.6) for all the subscales in all the groups". Similarly, they state that "The group of outpatients presented slightly worse model fit, not meeting conventional fit criteria; however, their fit may be regarded as acceptable."(L.355). If they did not meet conventional fit criteria, what was the rationale behind regarding it as acceptable?

I would suggest that the authors either phrase these conclusions more cautiously, where given criteria are laid out but are not met on absolute terms (such as table 7, where they state criteria to judge the RMSEA), or clarify how they derive these interpretations (references, convention?).

In the revised version of our manuscript, Cronbach's alpha ≥0.7 is now labelled as "acceptable", whereas ≥0.6 as "questionable" according to Crutzen and Peters (2017); the Results section has been modified accordingly (lines 437-440 in the revised manuscript). Although this convention to label alpha values has been widely accepted, this is not based on empirical research or logical reasoning (Hoekstra 2019). Moreover, as expressed by Schmitt (1996): "There is no sacred level of acceptable or unacceptable level of alpha. In some cases, measures with (by conventional standards) low levels of alpha may still be quite useful." Consequently, as advised by Taber (2018), the Discussion section has been supplemented with comments on the interpretability of Cronbach's alpha (lines 613-624 in the revised manuscript). We also appreciated McDonald's omega in estimation of internal consistency in the above mention comments. As McDonald's omega presents generally more favorable results than Cronbach's alpha in our research, the term "satisfactory" was kept in the Abstract, Results and Discussion sections (lines 35, 558 and 650) to describe a more "general" (i.e. composed of Cronbach's alpha and McDonald's omega) estimate of internal consistency.

To be more precise and less speculative in describing the results of confirmatory factor analysis (CFA) model fitting, it was stated whether a model meets conventional fit criteria or not (see lines 385-386 in the revised manuscript). Some expressions have been adjusted to provide a more precise description of whether the conventional model fit criteria were met (lines 408-409 and 626-629 in the revised manuscript).

2\. With regards the model comparison of a 1 to 2 to 3 to 4 factor model, it seems that the authors aimed to replicate the 4-factor model, yet it is not always clear which model criteria they employed for this decision. In some regards, the 3-factor model was favored (\"Moreover, parsimonious fit index and information criteria favored the simpler, 3-factor model, over the original 4-factor model in both in- and outpatients.\", L. 352), however the authors accept confirmation of the 4-factor structure. Although they elaborate on this in the discussion, and it replicates findings from other versions of the BMQ, I would advise to report more clearly (in the results section), which model criteria lead to the conclusion that \"little evidence against\" the 4-factor model makes it \"highly advisable\" (L.611).

Our decision to support the 4-factor model of BMQ-PL was based on 1) experimental data and 2) existing literature.

1\) Parsimony-corrected Comparative Fit Index as well as Akaike's and Bayesian Information Criteria favored the simpler, 3-factor model in the group of in- and outpatients. However, the differences were so minimal that appeared insignificant and could potentially disappear with follow-up study.

2\) Majority of the cross-cultural BMQ validation literature supports the use of the 4-factor model, including such languages as German (Mahler et al. 2010) or Czech (Matoulkova et al. 2013), which are spoken in countries bordering Poland and which are culturally similar to Poland.

As no solid evidence was found against two-dimensional General beliefs about medicines represented by Polish people, the original 4-factor model of the BMQ-PL was preserved.

Suitable information about this was added to the Results section (see lines 351-358 in the revised manuscript).

3\. After studying differences between subgroups, the authors employ a 2-factor-model in the subgroups, and a 4-factor-model in the pooled sample: "The analysis was performed separately for Specific and General scales in each group of respondents (Table 6) and together for all the subscales in the pooled sample (Table 7)". The motivation to split the analysis for Specific and General scales is not clear to me. Moreover, why is the approach not held constant for the pooled sample (specific and general separately)? Or alternatively, why apply a 4-factor model to the pooled sample, if shown before, that groups differ in how they respond to the items? It would be beneficial if the authors could clarify these approaches to guide the reader to a better understanding of their analyses.

The BMQ validation literature is inconsistent with the way of presenting the results of exploratory factor analysis (EFA). In order to give some examples:

• Horne et al. (1999), while developing the original tool, presented separate EFAs for Specific and General scales for a pool of selected patients as well as a single EFA with all the four subscales for a pooled sample of all the patients.

• Mahler et al. (2010), while validating the German BMQ version, used only a single EFA with all the four subscales for all the patients.

• Komninos et al. (2012), while validating the Greek BMQ version, applied only one type of EFA: separate for Specific and General scales for all the patients.

• Matoulkova et al. (2013), while validating the Czech BMQ version, replicated the approach of Horne et al. (1999) to use both types of EFA: separate for Specific and General scales for all the patients as well as a single EFA with all the four subscales for all the patients.

• Fall et al. (2014), while validating the French BMQ version, used no EFA at all.

• Gatt et al. (2017), while validating the Maltese BMQ version, applied only one type of EFA: a single EFA with all the four subscales for all the patients representing different illnesses.

In the original version of our manuscript we adapted the "richest" version of EFA: 1) separately for Specific and General scales for each groups of patients as well as 2) a single EFA with all the four subscales for a polled sample of patients; see: Horne et al. (1999) and Matoulkova et al. (2013). However, pooling all the patients lead us to a dead end, as multi-group CFA (MGCFA) indicated that the groups of patients may conceptualize BMQ-PL in different ways, and should not be combined as a result. On the other hand, it could be too confusing to report three independent EFAs with all the four subscales and the results would lack real value, as the associations between subscales of Specific and General scales have already been presented in Table 8 (numbering according to the original version of the manuscript).

As our results are already "rich" in content we decided to retain Table 6 (separate EFA for Specific and General scales for separate groups of patients), while discarding Table 7 (a single EFA with all the four subscales for a polled sample of patients) to enhance the clarity of the revised manuscript.

4\. It is mentioned that "Although the Likert scale data used in the questionnaires should be perceived as ordinal variables, the associations between the examined constructs were assessed with Pearson correlation coefficient (r) and were further explored with general linear modeling (GLM), i.e. parametric tests. This was to allow for multivariate modeling. However, corresponding non-parametric tests were performed where possible, and all yielded very similar results to the parametric ones."

This is somehow contradictory -- if the Likert scale is considered ordinal, I would expect the use of Spearman's rho (that is mentioned to result in "very similar results", which are however not reported), or more information on why this approach is feasible.

Parametric tests are more welcome in multidimensional analyses than non-parametric ones as they give more analytical potential (such as adjusting to covariates or testing interaction effects). There has been a long-lasting heated debate on whether parametric tests can be used to analyze Likert scale data, which is in fact ordinal. Thorough review of available literature (Carifio and Perla 2007, Mircioiu and Atkinson 2017, Glass et al. 1972) suggests that the parametric tests could be applied for majority of Likert scale data analyses. Nevertheless, two auxiliary analyses were run to test whether our parametric results are robust: 1) tests of normal distribution of residuals and 2) non-parametric equivalent test.

1\) Tests of normal distribution of residuals. In majority of correlation analyses the assumption of normal distribution of residuals was not significantly violated. The only severe violation was noted for the association between self-reported drug adherence and necessity, concern and necessity-minus-concern beliefs about medicines in the group of inpatients. This issue has been already discussed in the original version of the manuscript (see lines 679-688 in the revised manuscript).

2\) Non-parametric equivalent analyses. As already stated in "Data analysis" section of our manuscript, we run non-parametric equivalent tests, wherever possible, to check for similarities with corresponding parametric ones. In response to the Reviewer's comment, the revised version of the manuscript also reports the results of non-parametric tests together with parametric ones in table and graph form (S1 Table and S1 Figure in revised manuscript). The corresponding non-parametric and parametric association coefficients were very similar in all cases but two; this was acknowledged in the revised version of the manuscript (see Table 7 and 8 and lines 548-549 in the revised manuscript).

Minor:

1\. L. 352: 'parsimonious fit index and information criteria': Could you please specify the criteria you are referring to, e.g. BIC/AIC Table 3?

The indices were specified (see lines 349-350 in the revised manuscript).

2\. The proportion of male/female participants differs between groups, especially between in- and outpatients, where the majority of outpatients were female. I would suggest to elaborate on this further, or at least add this to the discussion as potential limitation, e.g. with regards to the generalizability of the findings.

The results of the χ2 test regarding the difference in the proportion of males to females across the groups of participants was added to the footnote of Table 2. This issue was briefly discussed in the Discussion section (see lines 694-697 and 700 in the revised manuscript) and summarized in the Limitation subsection of Discussion (see lines 720-722 in the revised manuscript) as advised by the Reviewer.
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